- 420 Downloads
Vismodegib is the first Hedgehog pathway inhibitor to be approved in the US, where it is indicated for the treatment of adults with metastatic basal cell carcinoma (BCC), or with locally advanced BCC that has recurred following surgery or who are not candidates for surgery, and who are not candidates for radiation. Vismodegib selectively and potently inhibits the Hedgehog signalling pathway by binding to Smoothened, thereby inhibiting the activation of Hedgehog target genes.
Oral vismodegib was effective in the treatment of patients with locally advanced (n = 63) or metastatic (n= 33) BCC, according to the results of an ongoing, noncomparative, multinational, pivotal, phase II trial (ERIVANCE BCC). In this trial (using a clinical cutoff date of 26 November 2010), the independent review facility overall response rate was 42.9% in patients with locally advanced BCC and 30.3% in patients with metastatic BCC. In both patients with locally advanced BCC and those with metastatic BCC, the median duration of response was 7.6 months and median progression-free survival was 9.5 months.
Oral vismodegib had an acceptable tolerability profile in patients with advanced BCC.
KeywordsMedulloblastoma Basal Cell Carcinoma Overall Response Rate Vismodegib Hedgehog Signalling Pathway
- 1.National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®): basal cell and squamous cell skin cancers (version 2.2012) [online]. Available from URL: http://www.nccn.org/professionals/physician_gls/pdf/nmsc.pdf [Accessed 2012 Mar 29]
- 5.F. Hoffmann-La Roche Ltd. FDA approves Erivedge (vismodegib) capsule, the first medicine for adults with advanced basal cell carcinoma [media release; online]. Available from URL: http://www.roche.com/media/media_releases/med-cor-2012-01-30.htm [Accessed 2012 Apr 4]
- 6.Genentech, Inc. Erivedge™ (vismodegib) capsule for oral use: US prescribing information [online]. Available from URL: http://www.gene.com/gene/products/information/erivedge/pdf/erivedge_prescribing.pdf [Accessed 2012 Mar 28]
- 13.Wong H, Chen JZ, Chou et al. Preclinical assessment of the absorption, distribution, metabolism and excretion of GDC-0449 (2-chloro-N-(4-chloro-3-(pyridin-2-yl)phenyl)-4-(methylsulfonyl)benzamide), an orally bioavailable systemic Hedgehog signalling pathway inhibitor. Xenobiotica 2009 Nov; 39(11): 850–61PubMedCrossRefGoogle Scholar
- 16.Graham RA, Hop CECA, Borin MT, et al. Single- and multiple-dose intravenous and oral pharmacokinetics of the Hedgehog pathway inhibitor vismodegib in healthy female subjects. Br J Clin Pharmacol. Epub 2012 Mar 27Google Scholar
- 17.Sharma M, Kang SP, Karrison T, et al. Evaluation of food effect on pharmacokinetics (PK) of GDC-0449 (G) in advanced solid tumor patients [abstract no. e1 3106]. 48th Annual Meeting of the American Society of Clinical Oncology; 2012 Jun 1–5; Chicago (IL)Google Scholar
- 19.Lum BL, Morrison GE, Chang I, et al. A phase I, open-label mass balance study of the hedgehog pathway inhibitor (HPI) GDC-0449 in healthy female subjects of non-childbearing potential [abstract no. 2558]. 46th Annual Meeting of the American Society of Clinical Oncology; 2010 Jun 4–8; Chicago (IL)Google Scholar
- 20.LoRusso PM, Piha-Paul SA, Colevas AD, et al. Pharmacokinetic assessment of drugdrug interaction potential when rosiglitazone or combined oral contraceptive is coadministered with vismodegib in patients with locally advanced or metastatic solid tumors [abstract]. 2011 AACR-NCI-EORTC International Conference: Molecular Targets and Cancer; 2011 Nov 12–16; San Francisco (CA)Google Scholar
- 22.Sekulic A, Migden MR, Oro AE, et al. Effiacy and safety of the Hedgehog pathway inhibitor vismodegib in patients with advanced basal cell carcinoma (BCC): ERIVANCE BCC study update [abstract no. 8579]. 48th Annual Meeting of the American Society of Clinical Oncology; 2012 Jun 1–5; Chicago (IL)Google Scholar